Cytodyn Inc (CYDY)

[clambottler]

OXFORD MANUSCRIPT IS PUBLISHED !!!!!

" inflammatory and cell prognostic markers did not markedly change immediately after treatment, although IL-6 tended to fall. "

" Future controlled trials will be informative. "

" Future controlled trials will be informative. "


CONCLUSIONS:

Manuscript accepted at Oxford Academic:
Conclusions
Leronlimab appeared safe and well tolerated. The high recovery rate suggested benefit, and those with lower inflammatory markers had better outcomes. Some but not all patients appeared to have dramatic clinical responses, indicating that unknown factors may determine responsiveness to leronlimab. Routine inflammatory and cell prognostic markers did not markedly change immediately after treatment, although IL-6 tended to fall. In some persons C-reactive protein clearly dropped only after the second leronlimab dose, suggesting that a higher loading dose might be more effective. Future controlled trials will be informative.

https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1583/5932277


" inflammatory and cell prognostic markers did not markedly change immediately after treatment, although IL-6 tended to fall. "

" Future controlled trials will be informative. "



Exactly my point

Additional Trials Necessary.

Good Luck.


See you Next February at $ 2.5 if lucky.

If it goes to $ 1.25 I may buy back in after a financing

Apparently they are running out of money quicky.


xxx.
xx.
x.